MX2014010423A - Sales de arginina utiles inmunologicamente. - Google Patents

Sales de arginina utiles inmunologicamente.

Info

Publication number
MX2014010423A
MX2014010423A MX2014010423A MX2014010423A MX2014010423A MX 2014010423 A MX2014010423 A MX 2014010423A MX 2014010423 A MX2014010423 A MX 2014010423A MX 2014010423 A MX2014010423 A MX 2014010423A MX 2014010423 A MX2014010423 A MX 2014010423A
Authority
MX
Mexico
Prior art keywords
arginine salts
immunologically useful
immunologically
useful
arginine
Prior art date
Application number
MX2014010423A
Other languages
English (en)
Other versions
MX346678B (es
Inventor
Siddhartha Jain
Stephanie Kay Dodd
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014010423A publication Critical patent/MX2014010423A/es
Publication of MX346678B publication Critical patent/MX346678B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención está en el campo de formas de sales de un compuesto inmunopotenciador y su formulación para uso in vivo. En particular la invención se relaciona a sales de arginina.
MX2014010423A 2012-03-07 2013-03-07 Sales de arginina utiles inmunologicamente. MX346678B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (2)

Publication Number Publication Date
MX2014010423A true MX2014010423A (es) 2014-09-22
MX346678B MX346678B (es) 2017-03-29

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010423A MX346678B (es) 2012-03-07 2013-03-07 Sales de arginina utiles inmunologicamente.

Country Status (18)

Country Link
US (1) US9320748B2 (es)
EP (1) EP2822947B1 (es)
JP (1) JP6325986B2 (es)
CN (1) CN104203946B (es)
AU (1) AU2013229466A1 (es)
CA (1) CA2865759C (es)
CY (1) CY1118091T1 (es)
DK (1) DK2822947T3 (es)
ES (1) ES2597755T3 (es)
HR (1) HRP20161354T1 (es)
HU (1) HUE030175T2 (es)
LT (1) LT2822947T (es)
MX (1) MX346678B (es)
PL (1) PL2822947T3 (es)
PT (1) PT2822947T (es)
RU (1) RU2014140336A (es)
SI (1) SI2822947T1 (es)
WO (1) WO2013131985A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
WO2012031140A1 (en) 2010-09-01 2012-03-08 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
EP2822581A2 (en) 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
AU2015238512B2 (en) 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
DE69334197T2 (de) 1992-03-02 2008-12-11 Novartis Vaccines And Diagnostics S.R.L. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
ATE229978T1 (de) 1994-07-01 2003-01-15 Chiron Corp Helicobacter proteine und impstoffe
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US20040005667A1 (en) 2000-07-03 2004-01-08 Giuloi Ratti Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
EP2335724A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
DK1549338T3 (da) 2002-10-11 2011-03-28 Novartis Vaccines & Diagnostic Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
WO2005084306A2 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
PL1858920T3 (pl) 2005-02-18 2016-12-30 Białka i kwasy nukleinowe z Escherichia coli związane z zapaleniem opon mózgowych/sepsą
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
JP2008544745A (ja) 2005-05-12 2008-12-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓのための免疫原性組成物
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1976557A2 (en) 2005-12-22 2008-10-08 Novartis Vaccines and Diagnostics S.r.l. Chlamydial antigens
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
SI2200642T1 (sl) 2007-10-19 2012-06-29 Novartis Ag Formulacije meningokoknega cepiva
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
AU2010255356A1 (en) 2009-06-01 2011-12-22 Novartis Ag Combinations of pneumococcal RrgB clades
AU2010258677B2 (en) * 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
MX2012002723A (es) * 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2012031140A1 (en) 2010-09-01 2012-03-08 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
US20140363461A1 (en) * 2011-09-01 2014-12-11 Fabio Bagnoli Adjuvanted formulations of staphylococcus aureus antigens

Also Published As

Publication number Publication date
EP2822947B1 (en) 2016-08-03
AU2013229466A1 (en) 2014-09-04
PL2822947T3 (pl) 2017-01-31
US20150125475A1 (en) 2015-05-07
EP2822947A1 (en) 2015-01-14
MX346678B (es) 2017-03-29
LT2822947T (lt) 2016-10-10
WO2013131985A1 (en) 2013-09-12
SI2822947T1 (sl) 2016-10-28
US9320748B2 (en) 2016-04-26
CN104203946A (zh) 2014-12-10
JP2015511957A (ja) 2015-04-23
CA2865759C (en) 2020-07-21
CY1118091T1 (el) 2017-06-28
CA2865759A1 (en) 2013-09-12
RU2014140336A (ru) 2016-04-27
CN104203946B (zh) 2017-03-22
PT2822947T (pt) 2016-09-26
ES2597755T3 (es) 2017-01-20
DK2822947T3 (en) 2016-09-19
JP6325986B2 (ja) 2018-05-16
HUE030175T2 (en) 2017-04-28
HRP20161354T1 (hr) 2016-12-02

Similar Documents

Publication Publication Date Title
MX2014010423A (es) Sales de arginina utiles inmunologicamente.
AR117799A2 (es) Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración
MX2012012530A (es) Derivados de n1-sulfonil-5-fluorpirimidinona.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
EP2895586A4 (en) DETERGENT COMPOSITION COMPRISING PHOSPHINOSUCCINIC ACID ADDITION PRODUCTS AND METHODS OF USE
EP3042652A4 (en) Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament
ECSP13012366A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
EP2872143A4 (en) DI- AND TRI-HETEROARYL DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
AU342936S (en) Insole
AU340528S (en) Insole
EP3004070A4 (en) ANTIOXIDATIVE HUMIC ACID DERIVATIVES AND METHOD FOR THE PREPARATION AND USE THEREOF
HK1202452A1 (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
BR112014000256A2 (pt) formulação de microemulsões transparentes e nutritivas
AU343717S (en) Sticking plaster used for medical purposes
ZA201306239B (en) Storage-stable formulation of paracetamol in aqueous solution
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
IN2014DN10658A (es)
EP3004069A4 (en) HUMINIC ACID DERIVATIVES AND METHOD FOR THE PREPARATION AND USE
MX2013014420A (es) Composiciones en gel.
EP2986112A4 (en) PREPARATION AND USE OF FULVINIC ACID DERIVATIVES

Legal Events

Date Code Title Description
FG Grant or registration